migraine headache. Migraine
Conditions
Interventions
Intervention 1: Control group: Tablet of 25 and 50 mg of topiramate of Daroupakhsh Co, Iran in dosage of 2 mg/kg/day single dose for two months. Intervention 2: Intervention group: One daily capsule o
Sponsors
Yazd University of Medical Sciences
Eligibility
Sex/Gender
All
Age
5 Years to 15 Years
Inclusion criteria
Inclusion criteria: children aged 5-15 years old having migraine headache based on International Headache Society Criteria having one or more headache attack per week having moderate or severe headache disability have not received omega-3 combinations within the past two months did not use any migraine preventive therapy
Exclusion criteria
Exclusion criteria: secondary headaches such as epilepsy or other neurologic disorders allergy to topiramat or omega-3 discontinuation of drugs usage for more than one week irregullar drugs usage
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Monthly frequency of headache. Timepoint: Before and two months after treatment. Method of measurement: Asking from patient.;Severity of headache. Timepoint: Before and two months after treatment. Method of measurement: Asking from patient.;Duration of headache. Timepoint: Before and two months after treatment. Method of measurement: Asking from patient.;Pediatric Migraine Disability score. Timepoint: Before and two months after treatment. Method of measurement: Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical side effects. Timepoint: Before and two months after treatment. Method of measurement: Clinical exam and asking from patients. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.Razieh Fallah
Yazd University of Medical Sciences
Outcome results
None listed